CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

**How to Use**

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| PURE STEAM | ADDITIONAL R | *USP41–NF36* | 4348 | 26-Oct-2018 | 1-Nov-2018 | *USP43–NF38* | *Second* | Delete |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | EQUIREMENTS | | | | | | *Supplement to USP41–NF36* | • *USP Reference Standards <11>* USP 1,4-Benzoquinone RS |
| TRANYLCYPROMINE TABLETS | PERFORMANCE TESTS/ *Dissolution <711>* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only. Change *System suitability* ? ?1S *(USP41)* *Sample*: *Standard solution* *Suitability requirements* *Tailing factor*: NMT 2.0 to: *System suitability* *Sample*: *Standard solution* *Suitability requirements* ? ?1S *(USP41)* *Tailing factor*: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ISOLEUCINE | IM<br>PUR<br>ITIES/*Related Compounds* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | NMT 2.0<br>This erratum applies to the new *USP-NF* ONLINE platform only.<br>Line 1 of *Standard solution*:<br>Change<br>USP L-Leucine RS<br>to:<br>USP L-Isoleucine RS |
| CYCLOPHOSPHAMIDE | ASSAY/ *Procedure* | *USP41–NF36* | 1123 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | In the variable definition in *Analysis*:<br>Change<br>$C_S$ = concentration of USP Cyclophosphamide RS in the *Standard solution* (mg/mL). [Note—Concentration is calculated on the anhydrous basis.]<br>C |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | $C_U$ = concentration of Cyclophosphamide in the *Sample solution* (mg/mL). [Note—Nominal concentration is calculated on the anhydrous basis.] to: $C_S$ = concentration of USP Cyclophosphamide RS in the *Standard solution* (mg/mL) $C_U$ = concentration of Cyclophosphamide in the *Sample solution* (mg/mL) |
| NAPROXEN TABLETS | IMPURITIES/*Organic Impurities* | *USP41–NF36* | 2865 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 3 of *System suitability solution*: Change 0.5 mg/mL of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | USP Naproxen RS and 0.5 µg/mL of USP Naproxen Related Compound A RS in *Diluent*, from *Standard stock solution 1* and *Standard stock solution 2*, respectively<br>to:<br>0.5 µg/mL of USP Naproxen Related Compound A RS from *Standard stock solution 2* and 0.5 mg/mL of USP Naproxen RS in *Diluent* |
| VITAMIN D ASSAY | ASSAY/ *Procedure 8* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 1 of *Aqueous potassium hydroxide solution*:<br>Change<br>800 mg<br>to: |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| SUMATRIPTAN NASAL SPRAY | ASSAY/ *Procedure* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | 800 g<br>This erratum applies to the new *USP-NF* ONLINE platform only.<br>In the variable definition in *Analysis*:<br>Change<br>$C_S$ = concentration of USP Sumatriptan Succinate Related Compound A RS<br>to:<br>$C_S$ = concentration of USP Sumatriptan Succinate RS |
| TRANEXAMIC ACID INJECTION | SPECIFIC TESTS | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only.<br>Change<br>*Dissolution* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | <*711*>: Meets the requirements to: *Sterility Tests* <*71*>: Meets the requirements |
| ACETAMINOPHEN ORAL SUSPENSION | IMPURITIES/*Organic Impurities* | *Revision Bulletin (Official August 01, 2018)* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only. Change *Solution B*: 0.2% trifluoroacetic acid in water to: *Solution B*: 0.2% trifluoroacetic acid in acetonitrile |
| MEPIVACAINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP41–NF36* | 2580 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 2 of Bupivacaine Related Compound B: Change *N*-(2,6-Dimethylphenyl)piperidine |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | -2-carboxamide. $C_{14}H_{20}N_2O$ 232.32 to: *N* -(2,6-Dimethylphenyl)piperidine -2-carboxamide hydrochloride. $C_{14}H_{20}N_2O \cdot HCl$ 268.79 |
| TEST FOR 1,6-ANHYDRO DERIVATIVE FOR ENOXAPARIN SODIUM | PROCEDURES /*Procedure* | *USP41–NF36* | 6108 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 2 of *Reduction suitability test*: Change 0.02%. to: 0.02. |
| LIDOCAINE | IM PURITIES/*Heavy Metals <231>* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only. Line 1 of *Acceptance criteria*: Change NMT 20 ppm ?1S *(USP41)* to: NMT 20 ppm ?(Official 1-Jan-2018) |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| TRIAMTERENE | IMPURITIES/*Organic Impurities* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only. Line 1 of *Standard stock solution 2*: Change 0.1 mg/mL of in *Diluent*. to: 0.1 mg/mL of USP Triamterene Related Compound A RS in *Diluent*. AND Line 1 of *Standard stock solution 3*: Change 0.1 mg/mL of USP Tranylcypromine Related Compound B RS in *Diluent*. to: 0.1 mg/mL of USP |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| ISOPROPYL ISOSTEARATE | ADDITIONAL REQUIREMENTS | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Triamterene Related Compound B RS in *Diluent*. This erratum applies to the new *USP-NF* ONLINE platform only. Line 2 of *USP Reference Standards <11>*: Change USP Isostearyl Isostearate RS to: USP Isopropyl Isostearate RS |
| LORAZEPAM TABLETS | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP41–NF36* | 2474 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 3 of USP Lorazepam Related Compound B RS: Change 266.13 to: 266.12 AND Line 4 of USP Lorazepam Related Compound C |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | RS: Change 303.15 to: 303.14 AND Line 4 of USP Lorazepam Related Compound D RS: Change 319.15 to: 319.14 |
| PIOGLITAZONE AND GLIMEPIRIDE TABLETS | IMPURITIES/*Organic Impurities: Glimepiride* | *USP41–NF36* | 3314 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Change *Table 3* to: *Table 4* AND Change *Table 4* to: *Table 5* AND Line 1 of *Mobile phase*: Change *Table 3* to: *Table 4* AND In the variable definition list in |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *Analysis*: Change *F* = relative response factor for each impurity (see *Table 4*) to: *F* = relative response factor for each impurity (see *Table 5*) AND Line 1 of *Acceptance criteria*: Change *Table 4* to: *Table 5* |
| BUMETANIDE TABLETS | IMPURITIES/*Organic Impurities/ Chromatographic system* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 1 of *Developing solvent system*: Change Methanol, cyclohexane, methanol, glacial acetic acid, and chloroform (2.5: 10: 10: 80) |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | to: Methanol, cyclohexane, glacial acetic acid, and chloroform (2.5: 10: 10: 80) |
| TRANYLCYPROMINE TABLETS | ASSAY/ *Procedure* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only. Change *Mobile phase*: *Methanol* and *Buffer* (30:70) *Diluent*: *Methanol*, water, and 0.05 N sulfuric acid ? VS*?1S (USP41)* (20:60:20) to: *Mobile phase*: *Methanol* and *Buffer* (30:70) ? ?(ERR 1-Oct-2018) *Diluent*: *Methanol*, water, and 0.05 N sulfuric acid ? |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| GLYCERYL TRICAPRYLATE | ASSAY/*Content of Triglycerides* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | VS*?1S (USP41)* (20:60:20) This erratum applies to the new *USP-NF* ONLINE platform only. Line 1 of *System suitability solution*: Change 20 mUSP Glyceryl Monocaprylate RSUSP Glyceryl Monocaprylate RSg/mL each of 1-monooctanoyl-rac-glycerol and 1-monodecanoyl-rac-glycerol in tetrahydrofuran to: 20 mg/mL each of 1-monooctanoyl-rac-glycerol and 1-monodecanoyl-rac-glycerol in |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | tetrahydrofuran |
| METHADONE HYDROCHLORIDE INJECTION | ASSAY/ *Procedure* | *USP41–NF36* | 2628 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | In the *Analysis*: Change Result = $(R_U/R_S) \times W \times 100$ to: Result = $(R_U/R_S) \times W$ |
| NIFEDIPINE EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/ *Dissolution <711>/Test 5* | *First Supplement to USP41–NF36* | 8369 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 1 of *Standard stock solution*: Change 50 mg of USP Nifedipine RS in *Diluent A* and water (50:50) to: 0.50 mg/mL of USP Nifedipine RS prepared as follows. Transfer a suitable amount of USP Nifedipine RS to an appropriate volumetric flask. Dissolve in 50% of the flask volume of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| PRAVASTATIN SODIUM | ADDITIONAL REQUIREMENTS | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | *Diluent A*. Dilute with water to volume.<br>AND<br>Line 1 of *Instrumental conditions/Analytical wavelength*: Change<br>238 nm<br>to:<br>338 nm<br>This erratum applies to the new *USP-NF* ONLINE platform only.<br>Line 2 of *USP Reference Standards* <*11*>: Change<br>USP Pravastatin Related Compound A RS<br>to:<br>USP Pravastatin 1,1,3,3-Tetramethyl |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| TRIAMTERENE | ADDITIONAL REQUIREMENTS | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | butylamine RS<br>This erratum applies to the new *USP-NF* ONLINE platform only.<br>Line 4 of *USP Reference Standards* <*11*>: Change<br>USP Doxazosin Related Compound A RS<br>to:<br>USP Triamterene Related Compound A RS |
| ORDINARY IMPURITIES | KEY FOR VISUALIZATION TECHNIQUES | *USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only.<br>Change<br>3. *Solution A*–Mix 850 mg of bismuth subnitrate with 40 mL of water |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | and 10 mL of glacial acetic acid.<br>4. *Solution B*–Dissolve 8 g of potassium iodide in 20 mL of water. Mix A and B together to obtain a Stock Solution which can be stored for several months in a dark bottle. Mix 10 mL of the Stock Solution with 20 mL of glacial acetic acid, and dilute with water to make 100 mL, to prepare the spray reagent.<br>to:<br>3. *Solution A*–Mix 850 mg of bismuth subnitrate with 40 mL of water |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | and 10 mL of glacial acetic acid.<br>*Solution B*–Dissolve 8 g of potassium iodide in 20 mL of water. Mix A and B together to obtain a Stock Solution which can be stored for several months in a dark bottle. Mix 10 mL of the Stock Solution with 20 mL of glacial acetic acid, and dilute with water to make 100 mL, to prepare the spray reagent.<br>AND<br>Update list numbers<br>5–23<br>to:<br>4–22 |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| LOXAPINE SUCCINATE | IMPURITIES/*Organic Impurities/Procedure* | *USP41–NF36* | 2486 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | In the variable definition list in *Analysis*: Add F = relative response factor (see *Impurity Table 1*) |
| INSULIN ASSAYS | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP41–NF36* | 6054 | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only. Delete USP Insulin RS |
| DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION | IMPURITIES/*Organic Impurities: Dorzolamide Hydrochloride* | *First Supplement to USP41–NF36* | Online | 28-Sep-2018 | 1-Oct-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | This erratum applies to the new *USP-NF* ONLINE platform only. In the first variable definition list in *Analysis*: Change $C_S$ = concentration of USP Doxazosin Related Compound D RS in the *Standard* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *solution* (mg/mL) to: $C_S$ = concentration of USP Dorzolamide Related Compound D RS in the *Standard solution* (mg/mL) AND In the second variable definition list in *Analysis*: Change $C_S$ = concentration of USP Doxazosin Related Compound B RS in the *Standard solution* (mg/mL) to: $C_S$ = concentration of |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | USP Dorzolamide Related Compound B RS in the *Standard solution* (mg/mL) |
| MILRINONE LACTATE INJECTION | IMPURITIES/*Organic Impurities* | *USP41–NF36* | 2748 | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Equation in *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (Mr_1/Mr_2) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ AND In the variable definition list: Delete $Mr_1$ = molecular weight of milrinone free base, 211.22 $Mr_2$ = molecular weight of milrinone lactate, 151.16 |
| HYDROCHLOROTHIAZIDE | PERFORMANCE | *USP41–NF36* | 2049 | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to* | Line 1 of *Empty capsules* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| CAPSULES | TESTS/ *Dissolution*/*Test 2* | | | | | | *USP41–NF36* | *solution*: Change Place 10 Capsules into to: Place 10 empty capsules into |
| ELASTOMERIC CLOSURES FOR INJECTIONS | PHYSICOCHEMICAL TESTS/*Heavy Metals* | *Revision Bulletin (Official January 01, 2018)* | Online | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Change *Test preparation*: Into a 50-mL color-comparison tube place 10.0 mL of *Solution S*. to: *Test preparation*: Into a 50-mL color-comparison tube pipet 10.0 mL of *Solution S* and dilute with water to 25 mL. Using a pH meter or short-range pH indicator paper as external indicator, adjust with 1 N acetic |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | acid or 6 N ammonium hydroxide to a pH of between 3.0 and 4.0, dilute with water to 40 mL, and mix. |
| AMIKACIN SULFATE INJECTION | ASSAY/ *Procedure* | *USP41–NF36* | 203 | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Variable definition list in *Analysis*: Change $C_U$ = nominal concentration of amikacin in the *Sample solution* to: $C_U$ = nominal concentration of amikacin in the *Sample solution* (mg/mL) |
| FISH OIL CONTAINING OMEGA-3 ACIDS CAPSULES | DEFINITION | *USP41–NF36* | 4620 | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 6: Change Scombroidae, to: Scombridae, |
| INSULIN LISPRO INJECTION | PRODUCT-RELATED SUBSTANCES AND | *USP41–NF36* | 2180 | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 3 of *Analysis*: Change Calculate the |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | IM PUR ITIES/*Related Substances* | | | | | | | percentage of insulin lispro, A-21 desamido insulin lispro, and other impurities in the portion of Insulin Lispro taken: to: Calculate the percentage of insulin lispro, A-21 desamido insulin lispro, and other impurities in the portion of Injection taken: |
| HAZARDOUS DRUGS - HANDLING IN HEALTHCARE SETTINGS | REFERENCES | *Revision Bulletin (Official December 01, 2017)* | Online | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Reference 37: Delete http://www.osha.gov/Publications/osha3151.html. |
| AMINOBENZOATE POTASSIUM | IM PURITIES/*Limit of Aniline and p-Toluidine* | *USP41–NF36* | 209 | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 3 of *System suitability*: Change [Note—The relative |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | retention times of aniline and *p*-toluidine are about 4.1 and 5.1 min, respectively.] to: [Note—The relative retention times of aniline and *p*-toluidine are 0.8 and 1.0, respectively.] |
| FISH OIL CONTAINING OMEGA-3 ACIDS DELAYED-RELEASE CAPSULES | DEFINITION | *USP41–NF36* | 4622 | 31-Aug-2018 | 1-Sep-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 7: Change Scombroidae, to: Scombridae, |
| RACEPINEPHRINE HYDROCHLORIDE | *USP Reference standards <11>* | *USP41–NF36* | 3565 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Add USP Epinephrine Bitartrate RS |
| MICONAZOLE NITRATE | ADDITIONAL REQUIREMENTS | *First Supplement to USP41–NF36* | Online | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | (Note: This errata applies to the new *USP-NF* ONLINE platform only.) Line 4 of *USP Reference* |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | *Standards* <*11*>: Change USP Doxazosin Related Compound C RS to: USP Miconazole Related Compound C RS AND Line 7 of *USP Reference Standards* <*11*>: Change USP Econazole Nitrate RS to: USP Miconazole Related Compound F RS |
| REAGENTS | REAGENTS, INDICATORS, AND SOLUTION | *USP41–NF36* | 5737 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 4 of *N-(2-Tetrahydrofuroyl)piperazine*: Change EMS-DOTTIKON, |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | S/*Reagent Specifications* | | | | | | | www.ems-dottikon.ch. to: Oakwood Chemical, www.oakwoodchemical.com. |
| BUPROPION HYDROCHLORIDE | IDENTIFICATION/*C. Identification Tests—General <191>, Chloride* | *USP41–NF36* | 573 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 1 of *Acceptance criteria*: Change Meets the requirements of test to: Meets the requirements of test *A* |
| RACEPINEPHRINE | *USP Reference standards <11>* | *USP41–NF36* | 3564 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Add USP Epinephrine Bitartrate RS |
| MICONAZOLE NITRATE | ASSAY/*Procedure* | *First Supplement to USP41–NF36* | Online | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | (Note: This errata applies to the new *USP-NF* ONLINE platform only.) Line 1 of *System suitability solution*: Change |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | 0.1 mg/mL of USP Miconazole Nitrate RS and 6 µg/mL of USP Econazole Nitrate RS in *Diluent*.<br>to:<br>0.1 mg/mL of USP Miconazole Nitrate RS and 6 µg/mL of USP Miconazole Related Compound F RS in *Diluent*. |
| ASSESSMENT OF EXTRACTABLES ASSOCIATED WITH PHARMACEUTICAL PACKAGING/DELIVERY SYSTEMS | REFERENCES | *USP41–NF36* | 7910 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 2 of reference 7: Delete http://webstore.ansi.org/RecordDetail.aspx?sku=ASTM%20F1980-07(2011)&source=msn&adgroup=astm. Accessed 19 March 2013. |
| FISH OIL | DEFINITION | *USP41–NF36* | 4617 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second* | Line 5: Change |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| CONTAINING OMEGA-3 ACIDS | | | | | | | *Supplement to USP41–NF36* | Scombroidae, to: Scombridae, |
| SODIUM FLUORIDE AND ACIDULATED PHOSPHATE TOPICAL SOLUTION | ASSAY | *First Supplement to USP41–NF36* | 8423 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 1 of *Sample solution*: Change 1.1 µg/mL of sodium fluoride to: 0.5 µg/mL of fluoride ion AND In the variable definition list in *Analysis*: Change $C_U$ = nominal concentration of sodium fluoride in the *Sample solution* (µg/mL) to: $C_U$ = nominal concentration of fluoride ion in the *Sample solution* (µg/mL) |
| REAGENTS | CHROMATOGRAPHIC CO | *USP41–NF36* | 5776 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 2 of *L73*: Delete [Note—Available |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | LUMNS/*Packings* | | | | | | | as Jordi-Gel DBV from www.jordiflp.com.] |
| DEXAMETHASONE SODIUM PHOSPHATE INJECTION | ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>* | *USP41–NF36* | 1204 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Delete USP Endotoxin RS |
| RACEPINEPHRINE INHALATION SOLUTION | ADDITIONAL REQUIREMENTS | *USP41–NF36* | 3564 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Add *USP Reference Standards <11>* USP Epinephrine Bitartrate RS |
| MICONAZOLE NITRATE | IMPURITIES/*Organic Impurities* | *First Supplement to USP41–NF36* | Online | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | (Note: This errata applies to the new *USP-NF* ONLINE platform only.) Line 1 of *Standard solution*: Change 1.2 µg/mL each of USP Miconazole Nitrate RS, USP Econazole Nitrate RS, USP Doxazosin |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Related Compound C RSUSP Doxazosin Related Compound C RS, USP Miconazole Related Compound F RS, and USP Miconazole Related Compound I RS in *Diluent* to: 1.2 µg/mL each of USP Miconazole Nitrate RS, USP Econazole Nitrate RS, USP Miconazole Related Compound C RS, USP Miconazole Related Compound F RS, and USP Miconazole |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Related Compound I RS in *Diluent* AND In the first variable definition list in *Analysis*: Change $C_S$ = concentration of USP Doxazosin Related Compound C RS, USP Doxazosin Related Compound F RS, USP Miconazole Related Compound I RS, or USP Miconazole Nitrate RS in the *Standard solution* (µg/mL) to: $C_S$ = concentration of USP |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Miconazole Related Compound C RS, USP<br>Miconazole Related Compound F RS, USP<br>Miconazole Related Compound I RS, or USP<br>Econazole Nitrate RS in the *Standard solution* (µg/mL) |
| GLUCAGON BIOIDENTITY TESTS | *B. In Vitro Cell-Based Bioidentity Test* | *First Supplement to USP41–NF36* | 8627 | 27-Jul-2018 | 1-Aug-2018 | *USP43–NF38* | *Second Supplement to USP41–NF36* | Line 1 of *Medium B*: Change Kreb's salt solution containing 0.3% (v/v) human serum albumen to: Krebs' salt solution containing 0.3% (v/v) human serum albumin AND |

| Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Line 1 of *Medium C*: change Kreb's salt solution containing 0.3% (v/v) human serum albumen to: Krebs' salt solution containing 0.3% (v/v) human serum albumin |

**Pagination**


- First page « First
- Previous page ‹ Previous
- …
- Page 6
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- …
- Next page Next ›

- Last page Last »